Biosynth Biological Technology Opens Its Doors in Suzhou
Biosynth, a prominent developer and supplier of essential raw materials and services for the diagnostics, vaccines, and pharmaceutical industries, is proud to announce the opening of its new facility, Biosynth Biological Technology, located in Lifebay, Suzhou, China. This cutting-edge site features state-of-the-art facilities, significantly enhancing Biosynth's abilities in project development and material supply within the domestic Life Science market.
Significant Opening Ceremony
The official opening ceremony attracted various local and national dignitaries, Life Science and Pharma customers, and valued partners of Biosynth. Attendees included key representatives from Biosynth’s Leadership Team and Board Representative Nico Haller from KKR.
Commitment to Innovation
Dr. Thomas Eisele, Chief Operations Officer, expressed excitement at the launch, stating, "We are thrilled to be formally opening Biosynth Biological Technology. This facility symbolizes our commitment to innovation and excellence, providing a crucial production site for materials and serving as a distribution hub for our customers in the region." This sentiment emphasizes how the facility aims to fulfill growing demands in the sector.
New Opportunities for IVD Companies
Philip Noone, Chief Commercial Officer, commented on the strategic significance of this new Lifebay facility. He noted, "Through our new Lifebay facility in Suzhou, Biosynth will serve IVD companies across China directly, with our comprehensive Biologics, Chemicals, and Complex Peptides offerings. Our facility enables us to provide unique diagnostic solutions for infectious diseases, oncology, and autoimmunity targeting emerging pathogens." The establishment of this site is a major milestone for the local industry, creating access to advanced diagnostic tools and services.
Enhanced Capabilities with Biosafety Level Labs
General Manager for China, Alessandra Vismara, highlighted the ambitious scale of the new project, stating, "This has been a significant endeavor to build and equip this facility. As part of the next phase, we will be commissioning our biosafety level 2 laboratories, allowing us to handle and supply a broader range of biological diagnostic tools. Additionally, enzyme development and production for local customers will round out the capabilities of these facilities." This statement indicates not only growth for Biosynth but also for the broader local industry.
About Biosynth
Biosynth is dedicated to supplying critical materials and securing life science supply chains through extensive research, manufacturing, and distribution facilities worldwide. Catering to the pharmaceutical, vaccine, and diagnostic sectors, where Chemistry meets Biology, Biosynth is positioned at the Edge of Innovation. With comprehensive end-to-end manufacturing capabilities, Biosynth specializes in Complex Chemicals, Peptides, and Biologics, all from one reliable partner. The company is headquartered in Staad, Switzerland, and is supported by prominent investors, including KKR and Ampersand Capital Partners. Explore more about their offerings by visiting their website.
Frequently Asked Questions
What is the purpose of the new Biosynth facility?
The new facility aims to enhance project development and material supply for the diagnostics and pharmaceutical industries in China.
Who attended the opening ceremony of the facility?
The opening ceremony featured local and national dignitaries, Life Science and Pharma customers, and Biosynth’s leadership team.
What services will the new facility offer?
The facility will provide unique diagnostic solutions, including Biologics, Chemicals, and Complex Peptides targeting infectious diseases and more.
Are there plans to expand the laboratory capabilities?
Yes, there are plans to commission biosafety level 2 laboratories to enhance the facility's capabilities to supply biological diagnostic tools.
Where is Biosynth headquartered?
Biosynth is headquartered in Staad, Switzerland, and operates globally to supply critical materials for life sciences.
